Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1991 2
1992 1
1993 2
1995 4
1996 2
1997 3
1998 4
1999 12
2000 5
2001 5
2002 9
2003 8
2004 11
2005 11
2006 10
2007 11
2008 16
2009 24
2010 22
2011 14
2012 20
2013 24
2014 18
2015 26
2016 38
2017 41
2018 25
2019 25
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

353 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Kristensen SL, et al. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14. Lancet Diabetes Endocrinol. 2019. PMID: 31422062
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (0·88, 0·83-0·95; p=0·001), hospital admission for heart failure by 9% (0·91, 0·83-0·99; p=0·028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular …
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (0·88, 0·83-0·95; p=0·001), hospital admission for heart failure by 9% ( …
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Rawshani A, et al. N Engl J Med. 2017 Apr 13;376(15):1407-1418. doi: 10.1056/NEJMoa1608664. N Engl J Med. 2017. PMID: 28402770 Free article.
Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. ...
Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 di …
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Kosiborod M, et al. Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18. Circulation. 2017. PMID: 28522450 Free PMC article. Clinical Trial.
BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disea …
BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-gluco …
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Campbell JM, Bellman SM, Stephenson MD, Lisy K. Campbell JM, et al. Ageing Res Rev. 2017 Nov;40:31-44. doi: 10.1016/j.arr.2017.08.003. Epub 2017 Aug 10. Ageing Res Rev. 2017. PMID: 28802803 Review.
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. Inzucchi SE, et al. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4. Diabetes Care. 2018. PMID: 29203583 Clinical Trial.
This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. ...CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in m …
This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to C …
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
INTERPRETATION: Our results do not fully support the efficacy of further intensified multifactorial intervention compared with current standard care for the prevention of a composite of coronary events, cerebrovascular events, and all-cause mortality. Nevertheless, our fin …
INTERPRETATION: Our results do not fully support the efficacy of further intensified multifactorial intervention compared with current stand …
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, George JT, Zinman B; EMPA-REG OUTCOME Investigators. Fitchett D, et al. J Am Coll Cardiol. 2018 Jan 23;71(3):364-367. doi: 10.1016/j.jacc.2017.11.022. J Am Coll Cardiol. 2018. PMID: 29348030 Free article. Clinical Trial. No abstract available.
Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B. Zhou Z, et al. Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009. Stroke. 2019. PMID: 30591006 Free PMC article. Clinical Trial.
Analysis of stroke subtypes found no effect on ischemic stroke (n=253, hazard ratio, 0.95; 95% CI, 0.74-1.22), a significant reduction for hemorrhagic stroke (n=30, hazard ratio, 0.43; 95% CI, 0.20-0.89) and no effect on undetermined stroke (n=29, hazard ratio, 1.04; 95% C …
Analysis of stroke subtypes found no effect on ischemic stroke (n=253, hazard ratio, 0.95; 95% CI, 0.74-1.22), a significant reduction
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL; REACH Registry Investigators. Cavender MA, et al. Circulation. 2015 Sep 8;132(10):923-31. doi: 10.1161/CIRCULATIONAHA.114.014796. Epub 2015 Jul 7. Circulation. 2015. PMID: 26152709
METHODS AND RESULTS: The Reduction of Atherothrombosis for Continued Health (REACH) registry is an international registry of patients at high risk of atherothrombosis or established atherothrombosis. ...
METHODS AND RESULTS: The Reduction of Atherothrombosis for Continued Health (REACH) registry is an international registry of patients …
Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.
Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, Imperatore G. Gregg EW, et al. Lancet. 2018 Jun 16;391(10138):2430-2440. doi: 10.1016/S0140-6736(18)30314-3. Epub 2018 May 18. Lancet. 2018. PMID: 29784146 Free article.
INTERPRETATION: Declining rates of vascular disease mortality are leading to a diversification of forms of diabetes-related mortality with implications for clinical management, prevention, and disease monitoring. ...
INTERPRETATION: Declining rates of vascular disease mortality are leading to a diversification of forms of diabetes-related mortality with i …
353 results
Jump to page
Feedback